田紅潮,毛 璞,肖詠梅,楊亮茹,屈凌波
(河南工業(yè)大學(xué) 生物工程學(xué)院,河南 鄭州 450000)
勃起功能障礙(ED)是一種常見的男性疾病并且患病率隨著年齡的增長而增加.磷酸二酯酶5抑制劑(PDE5i)被推薦作為治療ED的一線藥物[1],阿伐那非是新興的磷酸二酯酶5抑制劑的一種.根據(jù)GOSS的調(diào)查,ED在美國的發(fā)病率為33.7%[2].保守估計(jì),全球有1.5億的男性有不同程度的ED,2025年將翻一番達(dá)到3.22億人[3].根據(jù)張慶江等對(duì)北京、廣州、重慶進(jìn)行的調(diào)查,發(fā)現(xiàn)中國≥40歲人群ED患病率高達(dá)40.2%[4].阿伐那非(avanafil,StendraTM)是一種于2012年4月獲US-FDA批準(zhǔn)用于治療ED的口服速效的高選擇性磷酸二酯酶5抑制劑(PDE5i)[5].與其他PDE5i相比,阿伐那非選擇性更高,起效更快,副作用更少[6],預(yù)計(jì)將會(huì)有非常大的市場(chǎng)前景.基于此,很有必要研發(fā)其仿制藥,并在其基礎(chǔ)上開發(fā)出藥效更好、副作用更小、廉價(jià)易得的類似藥,基于阿伐那非的結(jié)構(gòu)(結(jié)構(gòu)式見圖1),合成了阿伐那非的類似物(見圖2).
本文按照酰胺縮合條件優(yōu)化的方法[7]合成了8種未見文獻(xiàn)報(bào)道的阿伐那非類似物.本研究以4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯(1)為原料,先進(jìn)行酯的水解,再與R基團(tuán)進(jìn)行酰胺縮合反應(yīng),合成了8種阿伐那非類似物(如表1所示).所合成的產(chǎn)物均經(jīng)1H NMR、13C NMR、ESI-MS得到驗(yàn)證.
圖1 阿伐那非的結(jié)構(gòu)式
Bruker Avance 400型超導(dǎo)核磁共振儀,瑞士Bruker公司;ICPMS7700型電感耦合等離子體質(zhì)譜儀,深圳華普通用科技有限公司;WQF-510型傅立葉變換紅外光譜儀,北京北分瑞利分析儀器;X-4型數(shù)字顯微熔點(diǎn)測(cè)定儀,北京福凱科儀科技有限公司;DF-101D集熱式恒溫加熱磁力攪拌器、旋轉(zhuǎn)蒸發(fā)器RE-2000B、SHD-D(Ⅲ)循環(huán)水式真空泵均為鞏義市予華儀器有限責(zé)任公司;DZF-6020真空干燥箱,上海申賢恒溫設(shè)備廠.
4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯(C18H21ClN4O4)(1,實(shí)驗(yàn)室自制);1-甲基哌嗪(C5H12N)、2-氯芐胺(C7H8ClN)、對(duì)甲氧基苯胺(C7H9NO)、L-苯丙氨醇(C9H13NO)、芐胺(C7H9N)、N-甲基芐胺(C8H11N)、L-亮氨醇(C6H15NO)、α-甲基芐胺(C8H11N)、1-乙基-3-(3-二甲基氨基丙基)碳化二亞胺鹽酸鹽(EDCI)和1-羥基苯并三唑水合物(HOBt)均購自阿拉丁試劑有限公司、二甲基亞砜(DMSO)、四氫呋喃(THF)、三乙胺(Et3N)等均為分析純.
圖2 阿伐那非類似物的合成路線
1.2.1 4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸(2)的合成
在50 mL圓底燒瓶中加入2.5 mmol 4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯(1),用體積比為VDMSO∶VTHF=1∶1的混合溶液溶解,再加入8 mL 10%的NaOH水溶液,室溫下攪拌,反應(yīng)結(jié)束后向混合物中加入25 mL 10%的檸檬酸水溶液,35 ℃下,減壓蒸餾除去THF,析出白色固體,抽濾,濾餅用蒸餾水洗滌,真空干燥6 h,得到化合物2,白色粉末狀固體.產(chǎn)物純度較高,不需要提純,直接進(jìn)行下一步反應(yīng).
1.2.2 阿伐那非類似物的合成
在50 mL圓底燒瓶中加入0.5 mmol化合物2,用DMF溶解,再加入0.6 mmol R,依次加入0.6 mmol 1-乙基-3-(3-二甲基氨基丙基)碳二亞胺鹽酸鹽(EDCI)、0.6 mmol 1-羥基苯并三唑水合物(HOBt)和1.0 mmol三乙胺(Et3N),磁力攪拌反應(yīng)混合物,反應(yīng)結(jié)束后把反應(yīng)液倒入18 mL飽和NaHCO3溶液中,乙酸乙酯萃取,有機(jī)層用飽和食鹽水洗滌,通過無水硫酸鈉干燥,在減壓旋蒸下除去溶劑,殘留物通過硅膠柱色譜純化,得到阿伐那非類似物.
化合物1(實(shí)驗(yàn)室自制):m.p.:86~88 ℃;1H NMR(400 MHz,DMSO-d6)δ:8.53(q,J=6.4 Hz,1H,NH),8.48(d,J=6 Hz,1H,Pyrimidine-H),7.42(dd,J=2 Hz,J=4.4 Hz,1H,Ph-H),7.29(d,J=8.4 Hz,1H,Ph-H),7.08(d,J=8.4 Hz,1H,Ph-H),4.81(m,1H,OH),4.55(t,J=7.6 Hz,2H,Ph-CH2),4.21(q,J=6.8 Hz,2H,OCH2CH3),4.13~4.08(m,1H,Pyrrolidine-H),3.82(d,J=1.6 Hz,3H,OCH3),3.63-3.58(m,1H,Pyrrolidine-H),3.51~3.45(m,2H,Pyrrolidine-H),3.35~3.31(m,1H,Pyrrolidine-H),2.02~1.83(m,4H,Pyrrolidine-H),1.26(t,J=7.2 Hz,3H,OCH2CH3);1H NMR(400 MHz,DMSO-d6,D2O)δ:8.47(q,J=5.6 Hz,1H,NH),8.42(d,J=2.4 Hz,1H,Pyrimidine-H),7.35(t,J=1.5 Hz,1H,Ph-H),7.25(d,J=8.4 Hz,1H,Ph-H) 7.03(dd,J=2.5,8.4 Hz,1H,Ph-H),4.51(d,J=6.5 Hz,2H,Ph-CH2),4.17(q,J=7.1 Hz,2H,OCH2CH3),4.07(s,1H,Pyrrolidine-H),3.77(d,J=1.1 Hz,3H,OCH3),3.60~3.52(m,1H,Pyrrolidine-H),3.48~3.40(m,2H,Pyrrolidine-H),3.30(dd,J=7.5,10.3 Hz,1H,Pyrrolidine-H),1.95~1.81(m,4H,Pyrrolidine-H),1.22(t,J=7.1 Hz,3H,OCH2CH3); IR(KBr,cm-1)σ:3340,1674,1525,1257,804; ESI-MS(m/z):421.25 [M+H]+.
表1阿伐那非類似物匯總
Tab. 1Avanafilanaloguessummary
化合物2:產(chǎn)率95.1%,m.p.:202~204 ℃;1H NMR(400MHz,DMSO-d6,D2O)δ:8.37(s,1H,Pyrimidine-H),7.35(d,J=8.2 Hz,1H,Ph-H),7.24(s,1H,Ph-H),7.04(d,J=8.2 Hz,1H,Ph-H) 4.52(s,2H,Ph-CH2),4.06(s,1H,Pyrrolidine-H),3.78(s,3H,OCH3),3.57(d,J=10.4 Hz,1H,Pyrrolidine-H),3.45(s,2H,Pyrrolidine-H),3.32(t,J=9.0 Hz,1H,Pyrrolidine-H),1.91(s,2H,Pyrrolidine-H),1.82(s,2H,Pyrrolidine-H); ESI-MS(m/z):393.25 [M+H]+.
化合物1的水解是一個(gè)很簡(jiǎn)單的反應(yīng).化合物1經(jīng)過水解得到4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸(化合物2)(如圖2所示).本文參考蔣慧敏[8]學(xué)位論文中的水解方法,用四氫呋喃(THF)作溶劑對(duì)原料進(jìn)行溶解,加入10%的NaOH水溶液后,發(fā)現(xiàn)混合物中有分層現(xiàn)象.因?yàn)橛袡C(jī)相和水相無法充分混溶,不僅反應(yīng)時(shí)間長,而且原料無法完全反應(yīng),產(chǎn)率較低.參考Yamada等人[9]專利文獻(xiàn)的方法,用二甲基亞砜(DMSO)作溶劑,原料完全溶解后加入10%的NaOH水溶液,立刻有原料析出,即使在超聲下也無法完全溶解,使得產(chǎn)品的純度和產(chǎn)率較低.通過大量實(shí)驗(yàn)發(fā)現(xiàn),采用混合溶劑法,即使用體積比為VDMSO∶VTHF=1∶1的混合溶液溶解原料,不僅原料可以充分溶解,而且反應(yīng)得到的產(chǎn)品產(chǎn)率和純度都較高.
在對(duì)水解得到的化合物2進(jìn)行后處理時(shí),如果處理不當(dāng)也會(huì)使產(chǎn)率降低.實(shí)驗(yàn)中發(fā)現(xiàn),反應(yīng)結(jié)束后,如果先旋蒸除去四氫呋喃,加入一定量的10%的檸檬酸水溶液后,立刻有大量白色沉淀產(chǎn)生,而且有相當(dāng)量的無須的淡黃色固體產(chǎn)生,附著在瓶壁上不易脫離下來,造成產(chǎn)品損失,而且在抽濾后濾液中會(huì)有少量白色懸浮物且不易回收,也會(huì)造成產(chǎn)品損失;反應(yīng)結(jié)束后如果先加入一定量的10%的檸檬酸水溶液再進(jìn)行旋蒸,隨著溶液中四氫呋喃的慢慢減少,會(huì)有白色沉淀慢慢析出,四氫呋喃除盡進(jìn)行抽濾,得到白色粉末狀的固體而且濾液為無色透明的液體,最終得到的產(chǎn)品雜質(zhì)較少,產(chǎn)率較高.產(chǎn)率為95.1%,產(chǎn)物純度較高,無須提純,直接進(jìn)行下一步反應(yīng).
化合物A-1:無色油狀物,產(chǎn)率82.7%;1H NMR(400 MHz,DMSO-d6),δ:7.85(s,1H,Pyrimidine-H),7.54(s,1H,Ph-CH2NH),7.42(d,J=1.5 Hz,1H,Ph-H),7.30(d,J=8.4 Hz,1H,Ph-H),7.06(d,J=8.6 Hz,1H,Ph-H),4.86(m,1H,OH),4.48(d,J=3.6 Hz,2H,Ph-CH2),4.07(s,1H,Pyrrolidine-H),3.81(s,3H,OCH3),3.63(s,1H,Pyrrolidine-H),3.48(s,4H,Piperazine-H),3.43(d,J=8.3 Hz,2H,CH2OH),3.32(t,J=8.8Hz,1H,Pyrrolidine-H),2.28(t,J=4.3 Hz,4H,Piperazine-H),2.17(s,3H,CH3),1.94~1.83(m,4H,Pyrrolidine-H);13C NMR(100MHz,DMSO-d6)δ:167.8,160.1,159.9,156.2,153.7,134.0,129.8,128.1,121.0,112.9,101.0,62.3,59.3,56.4,55.0(2C),47.6,46.0(2C),45.2,42.8,28.1,23.1; ESI-MS(m/z):497.2 [M+Na]+.
化合物A-2:白色固體,產(chǎn)率72.3%,m.p.:146~149 ℃;1H NMR(400 MHz,DMSO-d6),δ:9.17(d,J=5.8 Hz,1H,C(O)NH),8.75(t,J=5.8 Hz,1H,Ph-CH2NH),8.54(d,J=4.9 Hz,1H,Pyrimidine-H),7.44~7.41(m,2H,Ph-H),7.35~7.25(m,4H,Ph-H),7.07(d,J=8.5 Hz,1H,Ph-H),4.88(m,1H,OH),4.52(s,2H,Ph-CH2),4.49(d,J=5.9 Hz,2H,Ph-CH2),4.12(s,1H,Pyrrolidine-H),3.81(s,3H,OCH3),3.65(s,1H,Pyrrolidine-H),3.54~3.46(m,2H,CH2OH),3.34(d,J=9.9 Hz,1H,Pyrrolidine-H),1.99~1.84(m,4H,Pyrrolidine-H);13C NMR(100 MHz,DMSO-d6)δ:167.7,161.2,160.3,156.8,153.8,137.1,133.7,132.3,129.8,129.6,129.5,128.8,128.1,128.0,127.6,121.1,113.0,98.5,62.4,59.4,56.4,47.8,42.7,28.1,23.1; ESI-MS(m/z):516.23 [M+H]+.
化合物A-3:白色固體,產(chǎn)率78.7%,m.p.:192~194 ℃;1H NMR(400 MHz,DMSO-d6),δ:9.77(s,1H,C(O)NH),9.03(d,J=5.7 Hz,1H,Ph-CH2NH),8.58(d,J=9.6 Hz,1H,Pyrimidine-H),7.56(dd,J=2.1 Hz,J=5 Hz,2H,Ph-H),7.43(s,1H,Ph-H),7.31(dd,J=2.1 Hz,J=6.4 Hz,1H,Ph-H),7.08(d,J=8.5 Hz,1H,Ph-H),6.89(dd,J=2.1 Hz,J=4.9 Hz,2H,Ph-H),4.88(m,1H,OH),4.55(s,2H,Ph-CH2),4.12(d,J=13.8 Hz,1H,Pyrrolidine-H),3.82(s,3H,OCH3),3.73(s,3H,OCH3),3.65(d,J=4.5 Hz,1H,Pyrrolidine-H),3.55~3.48(m,2H,CH2OH),3.35(t,J=6.6 Hz,1H,Pyrrolidine-H),1.99~1.85(m,4H,Pyrrolidine-H);13C NMR(100 MHz,DMSO-d6),δ:166.1,161.2,160.2,157.2,155.8,153.8,133.7,132.5,129.8,128.1,122.7(2C),121.1,114.1(2C),113.1,99.2,62.4,59.4,56.5,55.6,47.8,42.7,28.1,23.1; ESI-MS(m/z):498.24 [M+H]+.
化合物A-4:白色固體,產(chǎn)率74.8%,m.p.:98~100 ℃;1H NMR(400 MHz,DMSO-d6),δ:9.05(d,J=5.4 Hz,1H,C(O)NH),8.39(d,J=10.0 Hz,1H,Pyrimidine-H),7.88(d,J=7.0 Hz,1H,Ph-CH2NH),7.39(s,1H,Ph-H),7.27~7.24(m,5H,Ph-H),7.17~7.14(m,1H,Ph-H),7.07(d,J=8.5 Hz,1H,Ph-H),4.90(m,1H,OH),4.83(t,J=5.7 Hz,1H,OH),4.49(d,J=4.8 Hz,2H,Ph-CH2NH),4.10(d,J=4.6 Hz,2H,Pyrrolidine-H,C(O)NHCH),3.81(s,3H,OCH3),3.62(d,J=8.6 Hz,1H,Pyrrolidine-H),3.51~3.42(m,4H,CH2OH),3.33(t,J=9.8 Hz,1H,Pyrrolidine-H),2.92(dd,J=5.2Hz,J=8.4Hz,1H,Ph-CH2),2.75(dd,J=4.5 Hz,J=9.0 Hz,1H,Ph-CH2),1.93~1.82(m,4H,Pyrrolidine-H);13C NMR(100 MHz,DMSO-d6),δ:167.2,161.1,160.2,156.6,153.8,139.9,133.7,129.8,129.6(2C),128.5(2C),128.1,126.3,121.0,113.1,99.0,63.4,62.6,59.4,56.5,53.2,47.8,42.6,37.1,28.1,23.1; ESI-MS(m/z):548.2 [M+Na]+.
化合物A-5:白色固體,產(chǎn)率71.9%,m.p.:58 ℃~60 ℃;1H NMR(400 MHz,DMSO-d6),δ:9.22(t,J=7.0 Hz,1H,C(O)NH),8.74(t,J=6.0 Hz,1H,Ph-CH2NH),8.48(d,J=5.2 Hz,1H,Pyrimidine-H),7.41(s,1H,Ph-H),7.33~7.23(m,6H,Ph-H),7.08(d,J=8.5 Hz,1H,Ph-H),4.86(m,1H,OH),4.52(d,J=5.5 Hz,2H,Ph-CH2),4.41(d,J=5.9 Hz,2H,Ph-CH2),4.10(s,1H,Pyrrolidine-H),3.82(s,3H,OCH3),3.63(s,1H,Pyrrolidine-H),3.50~3.44(m,2H,CH2OH),3.33(s,1H,Pyrrolidine-H),1.97~1.84(m,4H,Pyrrolidine-H);13C NMR(100 MHz,DMSO-d6)δ:167.5,161.3,160.3,156.6,153.8,140.3,133.7,129.8,128.7(2C),128.1,127.5(2C),127.1,121.1,113.1,98.7,62.4,59.4,56.5,47.6,42.5,41.2,28.1,23.1; ESI-MS(m/z):482.29 [M+H]+.
化合物A-6:無定形,產(chǎn)率90.1%;1H NMR(400 MHz,DMSO-d6),δ:7.93(s,1H,Pyrimidine-H),7.70(s,1H,Ph-CH2NH),7.45(d,J=1.8 Hz,1H,Ph-H),7.38~7.25(m,6H,Ph-H),7.08(d,J=8.5 Hz,1H,Ph-H),4.83(m,1H,OH),4.59(s,2H,Ph-CH2),4.50(d,J=5.2 Hz,2H,Ph-CH2),4.05(t,J=4.7 Hz,1H,Pyrrolidine-H),3.82(s,3H,OCH3),3.62(d,J=7.8 Hz,1H,Pyrrolidine-H),3.43(s,2H,CH2OH),3.30(s,1H,Pyrrolidine-H),1.99~1.82(m,4H,Pyrrolidine-H);13C NMR(100MHz,DMSO-d6)δ:170.8,160.2,159.8,155.8,153.7,137.7,134.1,129.8,129.1(2C),128.1,127.6(2C),127.5,121.0,112.9,101.2,62.4,60.2,59.4,56.4,47.7,42.8,35.7,28.1,23.2; ESI-MS(m/z):496.47 [M+H]+.
化合物A-7:白色固體,產(chǎn)率72.1%,m.p.:136~139 ℃;1H NMR(400 MHz,DMSO-d6),δ:9.19(d,J=4.6 Hz,1H,C(O)NH),8.42(s,1H,Pyrimidine-H),7.69(d,J=8.2 Hz,1H,Ph-CH2NH),7.41(s,1H,Ph-H),7.29(dd,J=2.0 Hz,J=6.4 Hz,1H,Ph-H),7.08(d,J=8.5 Hz,1H,Ph-H),4.90(m,1H,OH),4.65(t,J=5.8 Hz,1H,OH),4.51(d,J=5.8 Hz,2H,Ph-CH2),4.09(s,1H,Pyrrolidine-H),3.99(d,J=5.0Hz,1H,C(O)NHCH),3.82(s,3H,OCH3),3.63(d,J=7.2 Hz,1H,Pyrrolidine-H),3.48(d,J=4.6 Hz,2H,CH2OH),3.40(t,J=5.6Hz,1H,Pyrrolidine-H),3.34-3.30(m,2H,CH2OH),1.93~1.82(m,4H,Pyrrolidine-H),1.63~1.57(m,1H,(CH3)2CH),1.41~1.35(m,2H,(CH3)2CH-CH2),0.87(dd,J=3.7 Hz,J=6.6 Hz,6H,(CH3)2);13C NMR(100 MHz,DMSO-d6),δ:167.2,161.2,160.1,156.6,153.8,133.8,129.8,128.1,121.0,113.1,99.1,64.4,62.6,59.4,56.5,49.3,47.8,42.6,40.4,28.1,24.9,23.8,23.1,22.4; ESI-MS(m/z):514.2 [M+Na]+.
化合物A-8:無定形,產(chǎn)率80.8%;1H NMR(400 MHz,DMSO-d6),δ:9.13(d,J=4.8 Hz,1H,C(O)NH),8.56(s,1H,Ph-CH2NH),8.46(d,J=7.7 Hz,1H,Pyrimidine-H),7.39(s,1H,Ph-H),7.36~7.25(m,5H,Ph-H),7.23~7.19(m,1H,Ph-H),7.06(d,J=9.1 Hz,1H,Ph-H),5.08(d,J=7.1 Hz,1H,Ph-CH),4.92(m,1H,OH),4.52~4.48(m,2H,Ph-CH2),4.12(s,1H,Pyrrolidine-H),3.81(s,3H,OCH3),3.63(d,J=6.1 Hz,1H,Pyrrolidine-H),3.48(t,J=8.0 Hz,2H,CH2OH),3.36(s,1H,Pyrrolidine-H),1.99~1.83(m,4H,Pyrrolidine-H),1.44(d,J=7.1 Hz,2H,CH3);13C NMR(100 MHz,DMSO-d6)δ:167.8,161.3,160.3,156.8,153.8,145.7,133.7,129.8,128.7(2C),128.1,126.9,126.4(2C),121.1,113.0,98.8,62.7,59.5,56.4,48.4,47.8,42.6,28.2,23.1,22.8; ESI-MS(m/z):496.32 [M+H]+.
以4-(3-氯-4-甲氧基芐基氨基)-2-[(2S)-2-羥甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯為原料,經(jīng)過酯水解和酰胺縮合反應(yīng),合成了8種未見文獻(xiàn)報(bào)道的阿伐那非類似物,其結(jié)構(gòu)經(jīng)1H NMR、13C NMR及ESI-MS確證.本文合成的阿伐那非類似物,支持其生物活性及毒理的研究,為篩選出更理想的PDE5i服務(wù).